8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Apr 6, 2026·SEC
Praxis Precision Medicines, Inc.(PRAX)Earnings, Financials & Key Ratios
PRAX•NASDAQ
Price updated Jun 19, 2026
AboutPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$326M-63.2%
- Net Income-$303M-65.9%
- EPS (Diluted)-13.48-32.0%
- ROE-45.83%+35.4%
PRAX Key Insights
Praxis Precision Medicines, Inc. (PRAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Profits declining 37.4% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 25.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PRAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRAX Price & Volume
Praxis Precision Medicines, Inc. (PRAX) stock price & volume — 10-year historical chart
Loading chart...
PRAX Growth Metrics
Praxis Precision Medicines, Inc. (PRAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-53.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.72%
Return on Capital
10 Years-100.4%
5 Years-96.38%
3 Years-97.27%
Last Year-49.29%
PRAX Recent Earnings
Praxis Precision Medicines, Inc. (PRAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (40%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$3.20+10.6%
$3.58
Rev
—
$100,000
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$3.50-12.0%
$3.13
Rev
—
$66,667
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$3.36+2.6%
$3.45
Rev
—
$256,090
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$3.31+2.6%
$3.40
Rev
—
$59,440
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $3.20vs $3.58+10.6% | —vs $100,000 |
| Q1 2026 | Feb 19, 2026 | $3.50vs $3.13-12.0% | —vs $66,667 |
| Q4 2025 | Nov 5, 2025 | $3.36vs $3.45+2.6% | —vs $256,090 |
| Q3 2025 | Aug 4, 2025 | $3.31vs $3.40+2.6% | —vs $59,440 |
Based on last 12 quarters of dataView full earnings history →
PRAX Peer Comparison
Praxis Precision Medicines, Inc. (PRAX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 NRIX | 1.79B | 17.55 | -5.75 | 53.95% | -314.9% | -49.09% | 0.10 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 LGND | 5.51B | 274.88 | 44.84 | 60.4% | 55.95% | 16.19% | 0.44 | |
 OVID | 299.38M | 2.27 | -9.46 | 11.81% | -339.33% | -22.51% | 0.10 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 ENOV | 1.26B | 21.97 | -1.05 | 6.66% | -49.91% | -60.04% | 0.92 |
Compare PRAX vs Peers
Praxis Precision Medicines, Inc. (PRAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRAX Income Statement
Praxis Precision Medicines, Inc. (PRAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 2.45M | 8.55M | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | 249.53% | -100% | -100% |
Cost of Goods Sold | 1K | 679K | 0 | 0 | 154.44M | 86.77M | 152.41M | 140K | 128.84M |
COGS % of Revenue | - | - | - | - | - | 3545.81% | 1781.98% | - | - |
Gross Profit | -1K▲ 0% | -679K▼ 67800.0% | 0▲ 100.0% | 0▲ 0% | -154.44M▲ 0% | -84.32M▲ 45.4% | -143.86M▼ 70.6% | -140K▲ 99.9% | -128.84M▲ 0% |
Gross Margin % | - | - | - | - | - | -3445.81% | -1681.98% | - | - |
Gross Profit Growth % | - | -67800% | 100% | - | - | 45.4% | -70.61% | 99.9% | - |
Operating Expenses | 22.72M | 35.79M | 61.97M | 167.33M | 60.55M | 42.05M | 56.3M | 326.06M | 228.53M |
OpEx % of Revenue | - | - | - | - | - | 1718.59% | 658.31% | - | - |
Selling, General & Admin | 3.9M | 6.23M | 16.99M | 47.08M | 59.55M | 42.05M | 56.3M | 59.08M | 73.03M |
SG&A % of Revenue | - | - | - | - | - | 1718.59% | 658.31% | - | - |
Research & Development | 18.82M | 29.56M | 44.98M | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M | 284.3M |
R&D % of Revenue | - | - | - | - | - | 3545.81% | 1781.98% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -154.04M | -86.77M | -152.41M | 0 | -2M |
Operating Income | -22.72M▲ 0% | -35.79M▼ 57.5% | -61.97M▼ 73.1% | -167.33M▼ 170.0% | -214.99M▼ 28.5% | -126.37M▲ 41.2% | -200.16M▼ 58.4% | -326.2M▼ 63.0% | -357.33M▲ 0% |
Operating Margin % | - | - | - | - | - | -5164.41% | -2340.29% | - | - |
Operating Income Growth % | - | -57.53% | -73.15% | -170.03% | -28.48% | 41.22% | -58.39% | -62.96% | - |
EBITDA | -22.72M | -35.11M | -61.92M | -167.15M | -214.57M | -125.94M | -199.81M | -326.06M | -357.2M |
EBITDA Margin % | - | - | - | - | - | -5146.75% | -2336.1% | - | - |
EBITDA Growth % | - | -54.55% | -76.35% | -169.95% | -28.37% | 41.3% | -58.65% | -63.19% | -53.49% |
D&A (Non-Cash Add-back) | 1K | 679K | 50K | 182K | 419K | 432K | 358K | 140K | 132K |
EBIT | -26.27M | -35.6M | -61.97M | -167.33M | -213.99M | -126.37M | -200.16M | -303.27M | -352.9M |
Net Interest Income | -35K | 193K | 140K | 0 | 0 | 0 | 17.35M | 22.93M | 18.24M |
Interest Income | 92K | 193K | 140K | 0 | 0 | 0 | 17.35M | 22.93M | 18.24M |
Interest Expense | 127K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -3.68M | 193K | 140K | 271K | 957K | 3.1M | 17.35M | 22.93M | 30.8M |
Pretax Income | -26.4M▲ 0% | -35.6M▼ 34.8% | -61.83M▼ 73.7% | -167.06M▼ 170.2% | -214.03M▼ 28.1% | -123.28M▲ 42.4% | -182.82M▼ 48.3% | -303.27M▼ 65.9% | -326.53M▲ 0% |
Pretax Margin % | - | - | - | - | - | -5037.88% | -2137.48% | - | - |
Income Tax | 133K | -84K | -8K | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.5% | 0.24% | 0.01% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -26.54M▲ 0% | -35.51M▼ 33.8% | -61.82M▼ 74.1% | -167.06M▼ 170.2% | -214.03M▼ 28.1% | -123.28M▲ 42.4% | -182.82M▼ 48.3% | -303.27M▼ 65.9% | -326.53M▲ 0% |
Net Margin % | - | - | - | - | - | -5037.88% | -2137.48% | - | - |
Net Income Growth % | - | -33.83% | -74.08% | -170.24% | -28.11% | 42.4% | -48.3% | -65.88% | -53.62% |
Net Income (Continuing) | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M | -303.27M | -326.53M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -306.73▲ 0% | -348.24▼ 13.5% | -103.61▲ 70.2% | -58.96▲ 43.1% | -69.33▼ 17.6% | -18.69▲ 73.0% | -10.21▲ 45.4% | -13.48▼ 32.0% | -11.31▲ 0% |
EPS Growth % | - | -13.53% | 70.25% | 43.09% | -17.59% | 73.04% | 45.37% | -32.03% | -24.72% |
EPS (Basic) | -306.73 | -348.24 | -103.61 | -58.96 | -69.33 | -18.69 | -10.21 | -13.48 | - |
Diluted Shares Outstanding | 86.51K | 101.97K | 596.68K | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M | 28.88M |
Basic Shares Outstanding | 86.51K | 101.97K | 596.68K | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M | 28.88M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PRAX Balance Sheet
Praxis Precision Medicines, Inc. (PRAX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19.13M | 45.5M | 302.33M | 287.41M | 110.84M | 84.88M | 404.37M | 610.91M | 797.77M |
Cash & Short-Term Investments | 17.95M | 44.81M | 296.61M | 275.91M | 100.49M | 81.3M | 392.57M | 599.33M | 786.87M |
Cash Only | 17.95M | 44.81M | 296.61M | 138.7M | 61.62M | 81.3M | 215.37M | 357.33M | 536.33M |
Short-Term Investments | 0 | 0 | 0 | 137.21M | 38.87M | 0 | 177.19M | 242M | 250.53M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 3.58M | 11.8M | 11.58M | 10.91M |
Total Non-Current Assets | 703K | 2.2M | 851K | 5.34M | 4.29M | 3.07M | 78.74M | 327M | 662.43M |
Property, Plant & Equipment | 103K | 1.58M | 836K | 4.87M | 3.87M | 2.65M | 1.36M | 239K | 1.49M |
Fixed Asset Turnover | - | - | - | - | - | 0.92x | 6.28x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 600K | 0 | 0 | 0 | 0 | 0 | 76.96M | 0 | 267.38M |
Other Non-Current Assets | 0 | 620K | 15K | 472K | 416K | 416K | 416K | 326.76M | 660.94M |
Total Assets | 19.83M▲ 0% | 47.69M▲ 140.5% | 303.18M▲ 535.7% | 292.75M▼ 3.4% | 115.13M▼ 60.7% | 87.95M▼ 23.6% | 483.11M▲ 449.3% | 937.91M▲ 94.1% | 1.46B▲ 0% |
Asset Turnover | - | - | - | - | - | 0.03x | 0.02x | - | 0.00x |
Asset Growth % | - | 140.53% | 535.67% | -3.44% | -60.67% | -23.61% | 449.31% | 94.14% | 297.05% |
Total Current Liabilities | 5.14M | 6.82M | 15.72M | 38.43M | 34.34M | 15.75M | 37.55M | 59.77M | 50.24M |
Accounts Payable | 3.39M | 2.67M | 4.09M | 10.78M | 14.67M | 5.82M | 12.53M | 24.63M | 31.16M |
Days Payables Outstanding | 1000K | 1.43K | - | - | 34.68 | 24.46 | 30 | 64.21K | 81.76 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 110K | 1.44M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 2.82M | 1.39M | 0 | 0 | 0 |
Other Current Liabilities | 1.02M | 0 | 0 | 7.18M | 2.8M | 3.7M | 9.37M | 35.03M | 17.65M |
Current Ratio | 3.72x | 6.67x | 19.23x | 7.48x | 3.23x | 5.39x | 10.77x | 10.22x | 15.88x |
Quick Ratio | 3.72x | 6.67x | 19.23x | 7.48x | 3.23x | 5.39x | 10.77x | 10.22x | 15.88x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 2K | 763K | 0 | 3.5M | 4.68M | 2.53M | 110K | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 763K | 0 | 3.5M | 2.5M | 1.37M | 110K | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5.15M | 7.58M | 15.72M | 41.94M | 39.02M | 18.28M | 37.66M | 59.77M | 50.24M |
Total Debt | 0 | 1.46M | 763K | 4.31M | 3.5M | 2.5M | 1.37M | 110K | 1.44M |
Net Debt | -17.95M | -43.36M | -295.85M | -134.39M | -58.12M | -78.81M | -214M | -357.22M | -534.9M |
Debt / Equity | - | 0.04x | 0.00x | 0.02x | 0.05x | 0.04x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.50x |
Interest Coverage | -206.89x | - | - | - | - | - | - | - | - |
Total Equity | 14.68M▲ 0% | 40.11M▲ 173.2% | 287.46M▲ 616.6% | 250.81M▼ 12.7% | 76.11M▼ 69.7% | 69.67M▼ 8.5% | 445.45M▲ 539.4% | 878.14M▲ 97.1% | 1.41B▲ 0% |
Equity Growth % | - | 173.21% | 616.62% | -12.75% | -69.66% | -8.46% | 539.38% | 97.13% | 304.37% |
Book Value per Share | 169.72 | 393.36 | 481.76 | 88.62 | 24.77 | 10.57 | 24.88 | 39.02 | 48.82 |
Total Shareholders' Equity | 14.68M | 40.11M | 287.46M | 250.81M | 76.11M | 69.67M | 445.45M | 878.14M | 1.41B |
Common Stock | 1K | 1K | 4K | 5K | 5K | 13K | 14K | 15K | 15K |
Retained Earnings | -41.37M | -81.01M | -149.55M | -316.62M | -530.64M | -653.92M | -836.74M | -1.14B | -1.23B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1K | 0 | 0 | -176K | -173K | 0 | 654K | 0 | -1.59M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRAX Cash Flow Statement
Praxis Precision Medicines, Inc. (PRAX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.72M | -32.79M | -52.62M | -124.55M | -185.04M | -111.14M | -131.76M | -249.07M | -282.72M |
Operating CF Margin % | - | - | - | - | - | -4541.72% | -1540.48% | - | - |
Operating CF Growth % | - | -58.23% | -60.5% | -136.69% | -48.56% | 39.94% | -18.55% | -89.04% | -336.77% |
Net Income | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M | -303.27M | -326.53M |
Depreciation & Amortization | 1K | 679K | 50K | 182K | 419K | 432K | 358K | -3.45M | -855K |
Stock-Based Compensation | 579K | 0 | 5.21M | 22.69M | 28.59M | 24.86M | 41.36M | 33.94M | 15.22M |
Deferred Taxes | 3.65M | 0 | 0 | 2.09M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 127K | 668K | 696K | 1.41M | 1.75M | -121K | -1.58M | 1.03M | 26M |
Working Capital Changes | 1.46M | 1.38M | 3.24M | 16.13M | -1.78M | -13.03M | 10.92M | 22.68M | 3.45M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.67M | -837K | 960K | 7.27M | 3.89M | -8.86M | 6.71M | 12.1M | 8.25M |
Cash from Investing | -63K | -103K | 0 | -140.52M | 96.89M | 38.95M | -248.49M | -311.15M | -604.36M |
Capital Expenditures | -63K | -103K | 0 | -1.05M | -444K | -50K | 0 | -56K | -182K |
CapEx % of Revenue | - | - | - | - | - | 2.04% | - | - | - |
Acquisitions | 0 | 0 | 0 | 139.47M | -97.33M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -139.47M | 97.33M | 0 | 0 | 0 | 64K |
Cash from Financing | 37.8M | 59.76M | 304.42M | 107.59M | 10.46M | 91.87M | 514.32M | 702.17M | 1.26B |
Debt Issued (Net) | 1M | -633K | 0 | -763K | 0 | 0 | 0 | 0 | 202K |
Equity Issued (Net) | 36.8M | 60.39M | 304.42M | 105.71M | 9.56M | 91.59M | 512M | 704.26M | 1.27B |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -30M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 88K | 2.63M | 904K | 279K | 2.33M | -2.09M | -13.51M |
Net Change in Cash | 17.02M▲ 0% | 26.86M▲ 57.8% | 251.79M▲ 837.3% | -157.49M▼ 162.5% | -77.69M▲ 50.7% | 19.68M▲ 125.3% | 134.07M▲ 581.1% | 141.96M▲ 5.9% | 370.77M▲ 0% |
Free Cash Flow | -20.78M▲ 0% | -32.89M▼ 58.2% | -52.62M▼ 60.0% | -125.6M▼ 138.7% | -185.49M▼ 47.7% | -111.19M▲ 40.1% | -131.76M▼ 18.5% | -249.12M▼ 89.1% | -282.9M▲ 0% |
FCF Margin % | - | - | - | - | - | -4543.77% | -1540.48% | - | - |
FCF Growth % | - | -58.25% | -60% | -138.69% | -47.68% | 40.06% | -18.5% | -89.08% | -72.92% |
FCF per Share | -240.25 | -322.53 | -88.19 | -44.38 | -60.36 | -16.86 | -7.36 | -11.07 | -9.79 |
FCF Conversion (FCF/Net Income) | 0.78x | 0.92x | 0.85x | 0.75x | 0.86x | 0.90x | 0.72x | 0.82x | 0.87x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRAX Key Ratios
Praxis Precision Medicines, Inc. (PRAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -129.62% | -37.74% | -62.07% | -130.94% | -169.13% | -70.98% | -45.83% | -43.02% |
Return on Invested Capital (ROIC) | - | - | -232.34% | -239.92% | -2140.71% | -135.06% | -65.03% | -58.33% |
Gross Margin | - | - | - | - | -3445.81% | -1681.98% | - | - |
Net Margin | - | - | - | - | -5037.88% | -2137.48% | - | - |
Debt / Equity | 0.04x | 0.00x | 0.02x | 0.05x | 0.04x | 0.00x | 0.00x | 0.00x |
FCF Conversion | 0.92x | 0.85x | 0.75x | 0.86x | 0.90x | 0.72x | 0.82x | 0.87x |
Revenue Growth | - | - | - | - | - | 249.53% | -100% | -100% |
Related:PRAX Dividend History·PRAX Revenue History·PRAX Price History·PRAX P/E History·PRAX Financial Ratios·PRAX Institutional Holders
PRAX SEC Filings & Documents
Praxis Precision Medicines, Inc. (PRAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRAX Frequently Asked Questions
Praxis Precision Medicines, Inc. (PRAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Praxis Precision Medicines, Inc. (PRAX) saw revenue decline by 100.0% over the past year.
Praxis Precision Medicines, Inc. (PRAX) reported a net loss of $326.5M for fiscal year 2025.
Dividend & Returns
Praxis Precision Medicines, Inc. (PRAX) has a return on equity (ROE) of -45.8%. Negative ROE indicates the company is unprofitable.
Praxis Precision Medicines, Inc. (PRAX) had negative free cash flow of $282.9M in fiscal year 2025, likely due to heavy capital investments.